Lavipharm Q1 Pretax Profit €1.41M, Up 28.6% YoY
Lavipharm Q1 2026 Financial Results
Lavipharm SA (ATHEX: LAVI) reported a 28.6% year-over-year increase in earnings before tax from continuing operations for the first quarter of 2026, reaching €1.41 million. The company's EBITDA rose 11.0% to €3.13 million, while sales before rebate clawback increased 12.8% to €16.59 million.
Key Financial Highlights
Earnings Before Tax (Continuing Operations): €1.41 million (up 28.6% YoY)
EBITDA (Continuing Operations): €3.13 million (up 11.0% YoY)
Sales Before Rebate Clawback: €16.59 million (up 12.8% YoY)
Domestic Rx Pharmaceutical Sales: Up 32.2% YoY
Outlook
The company expects its group export activity for fiscal year 2026 to show growth compared to 2025, supporting its international expansion strategy.
The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.
More Headlines
Tokyo Core Inflation Slows, Remains Below BOJ Target
Tokyo Core Inflation Slows, Remains Below BOJ Target
…Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
…Australian Pension Fund HUB24 Faces Regulatory Scrutiny
Australian Pension Fund HUB24 Faces Regulatory Scrutiny
…